Neurovascular-Nugget 19_ Unraveling Stroke Clot Composition for Better Treatment

🧠🧠The clinical implications of this study are:

1. Thrombus composition could be an important factor underlying the variable efficacy of r-tPA in stroke patients. Knowing the composition of the occluding thrombus may help predict response to r-tPA and guide treatment decisions.
2. Imaging modalities like CT and MRI, which can identify RBC-rich thrombi, may be useful to predict r-tPA susceptibility. RBC-poor thrombi, not detectable by these methods, are likely to be r-tPA resistant.
3. For patients with r-tPA resistant thrombi (RBC-poor/platelet-rich), combining r-tPA with drugs targeting thrombus components like DNA (DNase-1) or VWF (diNAC) could be a promising approach to improve thrombolysis and recanalization rates.
4. A composition-tailored thrombolytic strategy, using r-tPA alone for RBC-rich thrombi and r-tPA + DNase-1/diNAC for RBC-poor thrombi, may expand the range of thrombi amenable to successful pharmacological lysis, especially benefiting patients currently failing r-tPA therapy.
5. If proven safe in terms of bleeding risk, a combination therapy targeting both fibrin and non-fibrin components could potentially be given to all patients, eliminating the need to determine thrombus composition beforehand.